- Home
- FUSB vs AVTX Comparison
FUSB vs AVTX Comparison
Compare FUSB & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUSB
- AVTX
- Stock Information
- Founded
- FUSB 1952
- AVTX 2011
- Country
- FUSB United States
- AVTX United States
- Employees
- FUSB N/A
- AVTX N/A
- Industry
- FUSB Major Banks
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- FUSB Finance
- AVTX Health Care
- Exchange
- FUSB Nasdaq
- AVTX Nasdaq
- Market Cap
- FUSB 73.3M
- AVTX 70.9M
- IPO Year
- FUSB N/A
- AVTX 2015
- Fundamental
- Price
- FUSB $12.99
- AVTX $6.90
- Analyst Decision
- FUSB
- AVTX Strong Buy
- Analyst Count
- FUSB 0
- AVTX 4
- Target Price
- FUSB N/A
- AVTX $33.00
- AVG Volume (30 Days)
- FUSB 2.0K
- AVTX 133.9K
- Earning Date
- FUSB 01-31-2025
- AVTX 11-07-2024
- Dividend Yield
- FUSB 1.74%
- AVTX N/A
- EPS Growth
- FUSB 5.90
- AVTX N/A
- EPS
- FUSB 1.40
- AVTX N/A
- Revenue
- FUSB $40,310,000.00
- AVTX $820,000.00
- Revenue This Year
- FUSB N/A
- AVTX N/A
- Revenue Next Year
- FUSB N/A
- AVTX N/A
- P/E Ratio
- FUSB $8.81
- AVTX N/A
- Revenue Growth
- FUSB 0.79
- AVTX N/A
- 52 Week Low
- FUSB $8.66
- AVTX $4.01
- 52 Week High
- FUSB $14.30
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- FUSB 50.96
- AVTX 35.20
- Support Level
- FUSB $12.34
- AVTX $6.04
- Resistance Level
- FUSB $13.00
- AVTX $7.17
- Average True Range (ATR)
- FUSB 0.48
- AVTX 0.87
- MACD
- FUSB -0.01
- AVTX -0.01
- Stochastic Oscillator
- FUSB 87.27
- AVTX 30.33
About FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals and other individuals.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).